Submitted by admin on Mon, 11/25/2019 - 21:56 snippet Shares in Adamis Pharmaceuticals have been poleaxed by an FDA decision to reject Zimhi, intended as a treatment for overdoses of opioid painkillers, because of manufacturing issues. Source Pharmaforum Headline FDA rejects Adamis opioid overdose therapy Zimhi, hitting share price News Tags Adamis Pharmaceuticals FDA Zimhi opioids opioid overdose